UK markets open in 1 hour 5 minutes


Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
17.000.00 (0.00%)
At close: 10:42AM EST
Sign in to post a message.
  • E
    Yesterday Angle posted news about the successful use of the Parsortix system with metastatic prostate cancer patients. That's 48 peer-reviewed publications.
  • g
    if you're not in this already you haven't been paying attention.
    will change cancer diagnosis as we know it.
    on a global scale.
    1 major pharma already on board confident of approval
  • E
    A snippet from recent news about a breast cancer study -
    Results from this study showed that the Parsortix system was able to harvest CTCs in a greater proportion of MBC patients (64%), compared to the antibody-based system (57%), and 99% of the cancer cells recovered by the Parsortix system had preserved morphology, allowing morphological analysis, whereas less than 1% of the cells recovered by the antibody-based system had preserved morphology. In addition, samples processed using the Parsortix system were also found to be of higher purity, with fewer blood cells present in the harvest.
    The proportion of MBC patients where cancer cells could be harvested for analysis using the Parsortix system also significantly exceeded the proportion of patients where cancer cells can be recovered from metastatic sites using tissue biopsy as less than 50% of MBC patients receive a successful tissue biopsy in accordance with US National Comprehensive Cancer Network (NCCN) clinical practice guidelines due to being too sick for the invasive procedure, inaccessibility of the tumour or failed procedures.
    The authors concluded that these results, combined with its ease of use, position the Parsortix system as the optimal system for integration into a routine cytopathology laboratory.
  • E
    More good news for business expansion.
    Contract secured for bespoke assay development 28/7/21
    ANGLE plc has agreed a pharma services contract with another new customer for its recently established pharma services business. ANGLE will develop immunofluorescence (IF) assays using its Parsortix® system to detect two specific protein markers expressed by circulating tumour cells (CTCs) and implicated in DNA damage repair (DDR). The new customer is a well-funded clinical stage development company with established commercialisation agreements with multiple global pharma companies. ........
    The first phase of work agreed covers the initial assay development and validation contract generating revenues of c. US$ 400,000 over a 12 month period.................
    Once developed, the new assays will remain in the ownership of ANGLE and be added to ANGLE's menu of pre-developed tests that can be offered to other pharma customers. .......
    ANGLE has established formal collaborations with world-class cancer centres and major corporates such as Abbott, Philips and QIAGEN, and works closely with leading CTC translational research customers.

    Assuming the FDA approval comes through this year, this stock will surely fly.
  • S
    FDA approval for Angle’s liquid biopsy will send this rocketing. Buying before the announcement. GLA and please do your own research